Searches for epitalon hit their highest point of the past three months in the week of 29 October 2026, and searches for pinealon, its sister peptide from the same St Petersburg laboratory, peaked the day before. That is not a coincidence. On 28 October the Department of Health and Human Services filed a policy saying it will not pursue pharmacies that compound six peptides, and epitalon is one of them. The people searching want to know three things: what it does, how much to take, and whether it is now legal.
Here is the caveat that gets dropped from almost every answer. Almost all of the human data you will see attached to epitalon belongs to a different substance, a calf pineal gland extract. The tetrapeptide itself has one small human study, no trial by injection, and a mechanism that the FDA named, in writing, as a cancer concern. A new independent lab study published in 2025 sharpened that concern rather than settling it. Let's dive in.
TLDR
What is epitalon? A synthetic four-amino-acid peptide (Ala-Glu-Asp-Gly, also sold as epithalon or AEDG), designed in Russia as a stand-in for epithalamin, an extract of calf pineal gland. It is sold as an anti-ageing "telomerase activator."
Results: In cells it lengthens telomeres, now confirmed by an independent UK lab. In mice it did not extend average lifespan but extended the lifespan of the longest-lived tenth. In humans given epitalon itself, one 20-day study measured a melatonin metabolite. The famous 12-year mortality results are from the extract, not the peptide.
Dosage: No validated protocol exists. Community courses run 10 to 20 days of daily injections, at doses that range widely and come from no human study. The mouse dose converts to roughly 0.2 mg for an adult, a fraction of what is commonly injected.
Safety: No human safety data by any route. The FDA's stated concern is that lengthening telomeres "could enable cells to evade senescence and become cancerous." The 2025 UK study found it lengthened telomeres in breast cancer cells too.
Legal Status (November 2026): Approved nowhere. Since 30 October an HHS draft policy says it will not take enforcement action against 503A pharmacies and physicians compounding epitalon under strict conditions, on prescription. That is not approval, not a bulks-list listing, and it does nothing for "research use only" vials.
What Is Epitalon, and Why Is Everyone Searching for It Now?
Let's get the identity straight, because the whole market depends on blurring it. Epitalon is a synthetic tetrapeptide, alanine-glutamate-aspartate-glycine. It was built by Vladimir Khavinson's group at the St Petersburg Institute of Bioregulation and Gerontology to imitate epithalamin, a polypeptide extract of calf pineal glands that the same group had studied since the Soviet era (Anisimov et al., 2003, Biogerontology, PMID 14501183).
Epithalamin is a different substance with an undefined composition. Epitalon is four residues you can write on a napkin. They share a lab, a name stem and a lot of product copy. They do not share evidence.
In our Google Trends pull for the US, interest in epitalon over the past 12 months, measured against a set of comparable longevity peptides, rose from an average of about 30 in the first four weeks to about 47 in the last four. Over the past 90 days it peaked in the week of 29 October. The related queries tell you what people want: "epitalon benefits," "epitalon dosage," "epitalon reddit," and, rising, pinealon, DSIP and ARA-290, the rest of the longevity shelf.
The trigger is regulatory. On 28 October 2026 HHS filed an "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances," published in the Federal Register on 30 October (HHS, 91 FR 68526). Epitalon is one of six peptides it covers, alongside BPC-157, KPV, MOTS-c, Semax and TB-500.
Epitalon is trending because a regulator stepped back, not because a human trial reported. The policy changed who can sell it. It did not change what is known about it.
How Does Epitalon Work?
Two mechanisms are claimed, and they are sold as one story about ageing.
The first is telomeres. Telomeres are the protective caps on the ends of chromosomes, and they shorten each time a cell divides. Telomerase is the enzyme that rebuilds them; most adult cells keep it switched off. In 2003 Khavinson's group reported that adding epitalon to telomerase-negative human fetal fibroblasts switched on the enzyme's catalytic subunit and lengthened telomeres (Khavinson et al., 2003, Bull Exp Biol Med, PMID 12937682). The paper is under three pages long.
The second is the pineal gland. In old rhesus monkeys, ten days of intramuscular epitalon raised evening melatonin and lowered evening cortisol, which is the basis for the sleep and circadian claims (FDA PCAC presentation on epitalon, July 2026).
Here is the part that the anti-ageing pitch leaves out. Switching telomerase back on is also exactly how most cancers make themselves immortal. Long telomeres in people are associated with a higher risk of several cancers (McNally et al., 2019, J Clin Invest, PMID 31380804). The mechanism that is the selling point and the mechanism that is the safety question are the same fact.
Epitalon's headline effect is lengthening telomeres. That is the promise and the risk in one sentence.
Epitalon vs Epithalamin vs Pinealon vs Melatonin
Epitalon is sold next to pinealon as a "bioregulator" pair, borrows epithalamin's human data, and is pitched for sleep against melatonin. Here is how they actually line up.
| Compound | What it is | Claimed use | Human evidence | Status (November 2026) |
|---|---|---|---|---|
| Epitalon | Synthetic tetrapeptide, Ala-Glu-Asp-Gly | Telomeres, ageing, sleep | One 20-day sublingual biomarker study; one 2002 retinal report from the originating group | Unapproved; covered by the HHS draft enforcement-discretion policy for 503A compounding |
| Epithalamin | Polypeptide extract of calf pineal gland, composition undefined | Ageing, mortality | Reports of lower mortality in elderly patients, all from the same group | Used clinically in Russia; not sold as a US drug |
| Pinealon | Synthetic tripeptide (Glu-Asp-Arg) from the same laboratory | Brain ageing, sleep | No published randomised human trial | Unapproved; not covered by the HHS policy |
| Melatonin | The pineal hormone itself, small molecule | Sleep timing, jet lag | Many randomised trials | Sold as a dietary supplement in the US |
The epithalamin row is the one that matters. When a product page cites a 12-year human study, it is citing the extract (Korkushko et al., 2006, Bull Exp Biol Med, PMID 17426848). The peptide in the vial was never in that study.
And if what you want is the melatonin effect the pineal story promises, melatonin is a cheap, studied, legal product. Epitalon's sleep claim rests on raising it indirectly.
What the Evidence Actually Shows
Epitalon has around 160 indexed papers, and roughly two-thirds carry Khavinson or his long-time collaborator Vladimir Anisimov as an author (ONPEPS epitalon library entry). For two decades that meant one source. In 2025 that finally changed, and not in a simple direction.
Published
| Finding | Model | Source | Status |
|---|---|---|---|
| Epitalon switched on telomerase and lengthened telomeres in telomerase-negative fetal fibroblasts | Human cells | Khavinson et al., 2003, Bull Exp Biol Med, PMID 12937682 | Peer-reviewed, originating group |
| Dose-dependent telomere lengthening in normal epithelial cells and fibroblasts through hTERT and telomerase; in two breast cancer cell lines, significant lengthening through ALT, a telomerase-independent pathway | Human cells | Al-Dulaimi et al., 2025, Biogerontology, PMID 40908429 | Peer-reviewed, independent (Brunel University London) |
| Monthly 5-day courses from 3 months of age to death: no change in mean lifespan; longest-lived 10% lived 13.3% longer; maximum lifespan up 12.3%; no change in total tumours; leukaemia 6-fold lower | Mice, 54 per group | Anisimov et al., 2003, Biogerontology, PMID 14501183 | Peer-reviewed, originating group |
| Slowed ageing markers and suppressed breast adenocarcinoma in tumour-prone HER-2/neu mice | Transgenic mice | Anisimov et al., 2002, Bull Exp Biol Med, PMID 12459848 | Peer-reviewed, originating group |
| Fewer malignant tumours and metastases in C3H mice | Mice | Kossoy et al., 2006, In Vivo, PMID 16634527 | Peer-reviewed, with the originating group |
| Positive clinical effect reported in 90% of patients with degenerative retinal disease | Rats and patients | Khavinson et al., 2002, Neuro Endocrinol Lett, PMID 12195242 | Peer-reviewed, originating group; numbers and controls not given in the abstract |
| Review: epitalon is "biologically active but clinically unproven" | Literature review | Jain et al., 2026, Int J Mol Sci, PMID 42884164 | Peer-reviewed review |
Unpublished, regulatory and borrowed
| Study | What was given | Result | Status |
|---|---|---|---|
| Night-shift workers, 40 women with low melatonin metabolites, 20 days | Sublingual epitalon or placebo spray, twice daily | Changes in urinary melatonin metabolite and clock gene expression | Described in the FDA review as small, short, unclear whether blinded, no safety data reported |
| 12-year study in elderly coronary patients | Epithalamin, the gland extract | 28% lower all-cause mortality reported | Not epitalon; four-page paper from the same group |
| FDA review for the July 2026 committee | Search of all available data | "No clinical data to support the safety of epitalon"; no study in insomnia; none by injection | Regulatory finding (FDA) |
| Registered clinical trials | None | None | No trial of epitalon is registered on ClinicalTrials.gov |
The Brunel paper deserves its own paragraph, because it is the most important epitalon study in twenty years. It is the first clear independent replication of the telomere effect, by a UK genome-maintenance lab with no stake in the peptide. In normal cells, it worked the way the marketing says.
In breast cancer cells it also lengthened telomeres, through ALT, the backup pathway some tumours use when telomerase is not enough. The authors note that ALT barely moved in normal cells. That is a cell culture finding and it does not show epitalon causes cancer. But it is the first independent evidence that bears on the FDA's concern, and it points the same way.
The mouse lifespan study is worth reading with the same care. The average mouse lived no longer. The gain was at the extreme tail, and leukaemia fell. That is a real, modest result, and it is not "adds years to your life."
The telomere effect is now independently real in a dish. So is its effect on cancer cells. Neither has been measured in a person.
Epitalon Dosage: What the Studies Used vs What People Report
Say it plainly: there is no validated epitalon protocol for humans. No study has injected it into people and measured anything. Everything below is an animal figure, a regulatory figure or a community convention, and you should know which is which.
What the studies used
The lifespan mice got 1 microgram per mouse, about 30 to 40 µg/kg, subcutaneously on five consecutive days each month (Anisimov et al., 2003, PMID 14501183). Run that through the FDA's standard body-surface conversion and you get roughly 2.4 to 3.3 µg/kg for a human, about 0.2 mg for a 70 kg adult per injection (FDA guidance on human equivalent dose).
That conversion is a starting-dose rule for drug developers, not a recommendation. But it shows something the vendor sheets do not: the dose behind the famous mouse result is small. Here, unlike most peptides, the community figures sit well above the animal ones, not below.
What the regulator saw
The nominations the FDA reviewed in July 2026 proposed subcutaneous injections at 3 mg/mL and 10 mg/mL for insomnia (FDA PCAC presentation). The HHS policy, as summarised by the law firm BakerHostetler, covers epitalon acetate in subcutaneous or intramuscular injectable forms "dispensed in intermittent courses" (BakerHostetler, 28 October 2026). Neither sets a dose.
What the community reports
Forum and clinic protocols run a course of daily injections for 10 to 20 days, repeated once or twice a year. Daily doses range from about 1 mg to 10 mg, with 5 mg and 10 mg the most repeated figures. The course structure is borrowed from the mouse schedule and from Russian use of the extract; the doses have no source you can read (ONPEPS, epitalon sourcing and quality).
The reconstitution math
Vials are commonly 10 mg, with 50 mg also sold. On a standard 100-unit (1 mL) insulin syringe:
| Vial | Bacteriostatic water added | Concentration | Units for 1 mg | Units for 5 mg | Units for 10 mg |
|---|---|---|---|---|---|
| 10 mg | 1 mL | 10 mg/mL | 10 | 50 | 100 |
| 10 mg | 2 mL | 5 mg/mL | 20 | 100 | Two full syringes |
| 50 mg | 2 mL | 25 mg/mL | 4 | 20 | 40 |
| 50 mg | 5 mL | 10 mg/mL | 10 | 50 | 100 |
Check your own numbers with the reconstitution calculator and the dosage calculator.
Two practical points follow. A 10-day course at 10 mg a day is 100 mg, ten small vials or two large ones. And a reconstituted multi-dose vial should be discarded 28 days after first use, so a vial opened for this spring's course is not the vial for autumn's.
No human dose exists. The mouse number converts to about 0.2 mg, the community injects 5 to 50 times that, and nobody has measured what either does in a person.
Epitalon Side Effects
Start with the honest baseline: there is no human safety dataset. The FDA found no clinical study assessing epitalon's safety, no adverse-event reports, and one sublingual study that did not report safety data (FDA PCAC presentation). No reports is not the same as no harm. Nobody is collecting them.
What exists:
- Mice. Lifetime monthly injections produced no toxic effect and no increase in total tumours, and epitalon did not damage bone marrow DNA (Anisimov et al., 2003, PMID 14501183).
- Community reports. Forum posts mostly describe injection-site redness and stinging, and some describe changes in sleep during a course. None of it has been collected, verified or compared with placebo.
- The telomere question. The FDA wrote that epitalon-induced telomere lengthening "raises concerns that continuous, chronic exposure to epitalon could enable cells to evade senescence and become cancerous," and that its carcinogenic potential "is unknown." The 2025 Brunel finding in breast cancer cells is the first independent data on that question.
The mouse cancer data cut the other way, with fewer tumours in three studies. But mice already carry long telomeres and abundant telomerase, which makes them a poor model for human telomere biology. Whether the reassurance or the concern applies to a person who injects a telomerase activator every year for a decade is a question no one has data to answer.
Then there is the vial. The FDA reviewed the certificates submitted with both nominations: identity matched, but there was no impurity, aggregation, endotoxin or bioburden data. In 2015 Belgian authorities identified epitalon in two seized illegal preparations (Vanhee et al., 2015, Drug Test Anal, PMID 25535022). A four-residue peptide is hard to get wrong. An injectable that is sterile and pyrogen-free is a different question, and research-grade certificates rarely answer it.
We found no published case report of serious harm attributed to epitalon. That is a fact about reporting, not a clean bill of health.
Who should not touch it: anyone with active, suspected or recent cancer, anyone pregnant or breastfeeding, and anyone with a family cancer history who has not discussed it with a doctor. The mechanism is the reason.
The Legal and Regulatory Situation
Epitalon has no marketing authorisation anywhere, no pharmacopeial monograph, and is not a component of any approved drug.
Category 2, then the vote
In September 2023 the FDA placed epitalon in Category 2 of its interim compounding policy, the list of substances that may present significant safety risks; by April 2026 its nomination had been withdrawn (FDA, Category 2 list). On 24 July 2026 the Pharmacy Compounding Advisory Committee voted 7 to 4, with one abstention, to recommend it for the 503A bulks list for insomnia, after FDA staff recommended against it on every criterion (ONPEPS, FDA peptide update July 2026).
What the HHS policy does
The new policy comes from the Office of the Secretary of HHS, not the FDA. It says HHS "does not intend to take enforcement action" against a state-licensed pharmacy, federal facility or licensed physician compounding with one of the six peptides, while the FDA builds the bulks list through rulemaking (HHS, Federal Register, 30 October 2026).
The conditions, as summarised by BakerHostetler and the American Med Spa Association:
- A valid patient-specific prescription, and a single active ingredient. No blends.
- Bulk peptide from an FDA-registered, CGMP-compliant manufacturer, with a certificate of analysis covering identity, purity, potency and contaminants.
- Serious adverse events and quality problems reported to FDA MedWatch and the state.
- Labelled "This is a compounded drug product. Not for resale."
- For epitalon, the acetate salt, by subcutaneous or intramuscular injection, in intermittent courses.
What it does not do
Read the notice itself and three words stand out: it calls the policy a "draft," says it "is not binding on HHS or the public," and says HHS may revisit it if "a safety signal or product quality issue arises." Comments on docket HHS-OASH-2026-0496 close on 13 November 2026.
It is not FDA approval. It does not put epitalon on the bulks list. It does not cover 503B outsourcing facilities. And it does not cover anything sold as a research chemical or dietary supplement (BakerHostetler; AmSpa). The "research use only" vial is exactly where it was on 27 October.
For what the six-peptide stopgap looked like before it was filed, see our October explainer on the temporary sale plan.
Sport
Epitalon is not named on the WADA Prohibited List. As an unapproved substance it may fall under S0, non-approved substances, which are prohibited at all times (WADA 2026 Prohibited List). If you are tested, ask your anti-doping organisation before, not after.
The Honest Take
Epitalon is a more interesting molecule than its marketing deserves. It does something measurable to telomeres, and as of 2025 a lab with no stake in it has confirmed that. That is more independent confirmation than most of the longevity shelf can claim.
But follow the evidence to where you would actually stand. No one has injected it into people and measured an outcome. The human mortality data belong to a gland extract. The lifespan mouse lived no longer on average. And the one effect that is now independently real is the effect the regulator flagged as a cancer risk, which the same independent lab then saw in cancer cells.
The HHS policy changes the supply chain, not the science. If you get epitalon from a 503A pharmacy on prescription, you get a product with a traceable manufacturer, a certificate and a clinician who wrote it down. That is a real improvement over a research vial. It is still the same untested drug.
Real effect in a dish, unknown effect in a person, and the effect is the risk. Lengthening your telomeres is not obviously something you want done blind.
FAQ
What is epitalon?
A synthetic four-amino-acid peptide (Ala-Glu-Asp-Gly) developed in Russia to imitate epithalamin, a calf pineal gland extract. It is sold as an anti-ageing telomerase activator. It is not approved as a drug anywhere.
What are the benefits of epitalon?
The claimed benefits are longer telomeres, slower ageing, better sleep and longer life. Telomere lengthening is shown in cells. Lifespan effects come from mice, where average lifespan did not change. No benefit has been shown in people given epitalon itself.
What is the epitalon dosage?
No validated human dose exists. Community courses run 10 to 20 days of daily injections at roughly 1 to 10 mg a day, once or twice a year. The mouse lifespan dose converts to about 0.2 mg for an adult. None of these figures come from a human trial.
How much bacteriostatic water for a 10 mg epitalon vial?
1 mL gives 10 mg/mL, so 5 mg is 50 units on a 100-unit syringe. 2 mL gives 5 mg/mL, so 5 mg is a full syringe. Use the reconstitution calculator to check your own vial.
Epitalon vs epithalon: is there a difference?
No. Epitalon, epithalon, epithalone and AEDG are spellings of the same tetrapeptide. Epithalamin is different: it is the gland extract, and it is the substance behind the human mortality studies.
Does epitalon really lengthen telomeres?
In cells, yes. The original 2003 Russian report was independently replicated in 2025 at Brunel University London. Nobody has shown it lengthens telomeres in a living person.
Does epitalon cause cancer?
There is no evidence it causes cancer in people, and mouse studies showed fewer tumours. But the FDA named telomere lengthening as a cancer concern, and the 2025 Brunel study found epitalon lengthened telomeres in breast cancer cells. Avoid it with any active or suspected cancer.
Is epitalon legal now?
Partly. Since 30 October 2026 an HHS draft policy says it will not take enforcement action against 503A pharmacies and physicians compounding epitalon on prescription, under strict conditions. It is still unapproved, and research-chemical sales are not covered.
Can a doctor prescribe epitalon?
Under the HHS policy, a licensed physician can prescribe it for compounding by a 503A pharmacy, which must source the peptide from an FDA-registered manufacturer with a valid certificate. The policy is a draft and can be revised or withdrawn.
What is the difference between epitalon and pinealon?
Both come from Khavinson's laboratory. Epitalon is a tetrapeptide sold for telomeres and ageing; pinealon is a tripeptide sold for brain ageing and sleep. Neither has a randomised human trial, and only epitalon is covered by the HHS policy.
Does epitalon help sleep?
It raised evening melatonin in old monkeys and changed a melatonin metabolite in one 20-day study of night-shift workers. No study has tested it in people with insomnia, the use an FDA committee recommended it for.
Is epitalon banned in sport?
It is not named on the WADA list, but as an unapproved substance it may fall under S0, which is prohibited at all times. Tested athletes should check with their anti-doping organisation.
Resources
Khavinson et al. (2003), Bull Exp Biol Med, epitalon induces telomerase and telomere elongation in human fibroblasts — https://pubmed.ncbi.nlm.nih.gov/12937682/
Al-Dulaimi et al. (2025), Biogerontology, independent replication in normal and breast cancer cell lines; telomerase and ALT pathways — https://pubmed.ncbi.nlm.nih.gov/40908429/
Anisimov et al. (2003), Biogerontology, lifespan and tumour incidence in mice — https://pubmed.ncbi.nlm.nih.gov/14501183/
Anisimov et al. (2002), Bull Exp Biol Med, epitalon in HER-2/neu transgenic mice — https://pubmed.ncbi.nlm.nih.gov/12459848/
Kossoy et al. (2006), In Vivo, epitalon and spontaneous carcinogenesis in C3H mice — https://pubmed.ncbi.nlm.nih.gov/16634527/
Khavinson et al. (2002), Neuro Endocrinol Lett, epitalon in retinitis pigmentosa — https://pubmed.ncbi.nlm.nih.gov/12195242/
Korkushko et al. (2006), Bull Exp Biol Med, epithalamin in elderly subjects; concerns the extract, not epitalon — https://pubmed.ncbi.nlm.nih.gov/17426848/
McNally et al. (2019), J Clin Invest, long telomeres and cancer risk — https://pubmed.ncbi.nlm.nih.gov/31380804/
Jain et al. (2026), Int J Mol Sci, narrative review of epitalon and epithalamin — https://pubmed.ncbi.nlm.nih.gov/42884164/
Vanhee et al. (2015), Drug Test Anal, epitalon identified in seized illegal preparations — https://pubmed.ncbi.nlm.nih.gov/25535022/
FDA (2026), epitalon presentation to the Pharmacy Compounding Advisory Committee, docket FDA-2025-N-6895 — https://www.fda.gov/media/193774/download
FDA (2026), July 23–24 Pharmacy Compounding Advisory Committee meeting page — https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
FDA (2026), Category 2 bulk drug substances list — https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
FDA (2005), guidance on estimating the maximum safe starting dose (human equivalent dose) — https://www.fda.gov/media/72309/download
HHS (2026), Federal Register, 91 FR 68526, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, docket HHS-OASH-2026-0496 — https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances
BakerHostetler (2026), legal alert summarising the HHS policy conditions and the epitalon route — https://www.bakerlaw.com/insights/hhs-issues-enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances/
American Med Spa Association (2026), HHS interim enforcement discretion for six peptides — https://www.americanmedspa.org/news/hhs-announces-interim-enforcement-discretion-for-six-peptides/
WADA (2026), Prohibited List — https://www.wada-ama.org/en/resources/2026-prohibited-list
ONPEPS, epitalon library entry, sourcing and cost pages — https://www.onpeps.com/peptides/epitalon
ONPEPS, FDA peptide update July 2026 — https://www.onpeps.com/blog/fda-peptide-update-july-2026
